United Therapeutics Corporation $UTHR Shares Bought by M&T Bank Corp

M&T Bank Corp lifted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 3,814.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 45,290 shares of the biotechnology company’s stock after purchasing an additional 44,133 shares during the period. M&T Bank Corp’s holdings in United Therapeutics were worth $22,068,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Darwin Global Management Ltd. purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at about $317,617,000. Baillie Gifford & Co. acquired a new position in United Therapeutics during the fourth quarter worth approximately $157,390,000. Balyasny Asset Management L.P. increased its position in United Therapeutics by 863.9% during the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after buying an additional 136,883 shares during the period. Sofinnova Investments Inc. purchased a new stake in United Therapeutics in the second quarter valued at approximately $34,055,000. Finally, Orbimed Advisors LLC purchased a new stake in United Therapeutics in the third quarter valued at approximately $48,167,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of UTHR opened at $572.85 on Friday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $607.89. The company has a market capitalization of $25.11 billion, a price-to-earnings ratio of 20.53, a price-to-earnings-growth ratio of 1.63 and a beta of 0.75. The firm has a 50-day simple moving average of $534.64 and a 200-day simple moving average of $493.24.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the company earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. Equities research analysts forecast that United Therapeutics Corporation will post 27.97 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on UTHR. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. TD Cowen lifted their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Finally, Bank of America upped their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a report on Tuesday, March 31st. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $601.50.

Insider Buying and Selling

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, April 20th. The stock was sold at an average price of $577.86, for a total transaction of $5,778,600.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,907,685.36. This trade represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christopher Patusky sold 1,000 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $578.88, for a total value of $578,880.00. Following the sale, the director directly owned 1,490 shares of the company’s stock, valued at approximately $862,531.20. This represents a 40.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 430,295 shares of company stock valued at $229,488,901 in the last ninety days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.